BetaEntity Annotation Prototype

Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

6articles mentioning drugs
9drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Tisagenlecleucel ×

Tisagenlecleucel

This drug is selected. Its supporting articles are shown below.

Articles mentioning Tisagenlecleucel

6 articles · page 1 of 1
axicabtagene ciloleuceltisagenlecleucelciltacabtagene autoleucelanakinramultiple myelomaDLBCLacute lymphoblastic leukaemiadiffuse large B-cell lymphomaICANSOrionClinic+1 more

…in over one-third of patients, especially in DLBCL treated with axicabtagene ciloleucel, while none were reported with tisagenlecleucel. Despite low mo…

brexucabtagene autoleucelbrexi-celtisagenlecleucelaxicabtagene ciloleuceltisa-celaxi-celmyelomatertiary oncology centrechemo refractory aggressive B-cell lymphomas

…l (axi-cel), 31 (42%) tisagenlecleucel (tisa-cel), and 11 (16%) brexucabtagene autoleucel (brexi-cel). Mean V2Vt was 48±19 days (median 42) for axi-cel, …

TisagenlecleucelKymriahTecartusbrexucabtagén autoleucelYescartaAxicabtagén ciloleucelECOG Performance Statushematologic malignanciesmantle cell lymphomadiffuse large B-cell lymphoma+5 more

…red in 80.8%, brexucabtagén autoleucel(Tecartus ) in 11.5%, and Tisagenlecleucel(Kymriah ) in 7.7 % of patients. The median age was 67.5 years (…

Axicabtagene Ciloleuceltisagenlecleucellisocabtagene maraleucelR/R LBCLChimeric antigen receptor (CAR) T-cell therapies

…act of Vein-to-vein Time in Patients With R/R LBCL Treated with Axicabtagene Ciloleucel. Blood Adv. 2025 Jun 10;9(11):2663–2676. doi: 10.1182/bloodadva…